Financial Performance - Revenue for the first quarter of 2025 increased by 20.21% to CNY 25,074,439.29, up from CNY 20,859,112.75 in the same period last year[10] - Net profit attributable to shareholders was a loss of CNY 8,582,701.78, an improvement of 5.22% compared to a loss of CNY 9,055,465.07 in Q1 2024[10] - Operating profit for Q1 2025 was a loss of ¥8,406,525.58, an improvement from a loss of ¥9,192,281.87 in Q1 2024[43] - Net profit for Q1 2025 was a loss of ¥8,582,701.78, compared to a loss of ¥9,055,465.07 in Q1 2024, showing a reduction in losses of approximately 5.2%[43] - The company reported a total operating profit of -¥6,628,413.05 for Q1 2025, slightly better than -¥6,982,801.43 in Q1 2024[45] Cash Flow - Operating cash flow improved significantly, with a net cash flow from operating activities of -CNY 8,197,355.91, a 50.94% reduction in cash outflow compared to -CNY 16,709,112.46 in the previous year[10] - Cash flow from operating activities for Q1 2025 was -¥8,197,355.91, an improvement compared to -¥16,709,112.46 in Q1 2024[47] - Total cash inflow from investment activities in Q1 2025 was ¥16,019,239.45, while cash outflow was ¥36,802,279.30, resulting in a net cash flow of -¥20,783,039.85[48] - Cash inflow from financing activities in Q1 2025 was ¥12,000,000.00, compared to ¥17,000,000.00 in Q1 2024, showing a decrease of approximately 29.4%[48] Assets and Liabilities - Total assets decreased by 2.00% to CNY 432,625,004.90 as of March 31, 2025, compared to CNY 441,465,037.83 at the end of 2024[10] - Total liabilities as of March 31, 2025, were ¥213,125,853.60, compared to ¥213,383,184.75 on December 31, 2024, showing a slight decrease of 0.12%[36] - The company's total equity decreased to ¥219,499,151.30 from ¥228,081,853.08, a reduction of approximately 3.77%[36] - Total current assets amounted to ¥240,677,602.73, a decrease from ¥247,334,903.32 on December 31, 2024, representing a decline of approximately 2.66%[34] Shareholder Information - The total number of ordinary shares remained at 85,847,126, with 6,488 shareholders[17] - Major shareholder Wang Jie holds 27.22% of the shares, while Tian Lifeng holds 5.71%[19] Operating Costs and Expenses - The company's gross profit margin decreased due to a 70.24% increase in operating costs, which outpaced revenue growth[11] - Total operating costs for Q1 2025 were ¥36,275,290.39, up from ¥30,698,379.49 in Q1 2024, indicating an increase of about 18.0%[41] - Research and development expenses for Q1 2025 were ¥7,231,154.86, compared to ¥6,033,462.71 in Q1 2024, indicating an increase of approximately 19.9%[41] Guarantees and Commitments - The company provided external guarantees totaling ¥30,000,000, with a remaining balance of ¥20,000,000[28] - The company has fulfilled its commitments regarding external guarantees and other major related transactions in a timely manner[25] Other Financial Information - The company reported a credit impairment loss of ¥1,105,592.94 in Q1 2025[43] - The company has no litigation or arbitration matters during the reporting period[24] - The company has no significant related party transactions that were not disclosed[24]
辰光医疗(430300) - 2025 Q1 - 季度财报